{
    "id": 26631,
    "fullName": "ASPH positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ASPH positive indicates the presence of the ASPH gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 444,
        "geneSymbol": "ASPH",
        "terms": [
            "ASPH",
            "AAH",
            "BAH",
            "CASQ2BP1",
            "FDLAB",
            "HAAH",
            "JCTN",
            "junctin"
        ]
    },
    "variant": "positive",
    "createDate": "05/29/2017",
    "updateDate": "01/02/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14119,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, PAN-301-1 demonstrated safety and preliminary efficacy, resulted in dose-dependent ASPH (HAAH)-specific B- and T-cell responses, and decreased PSA levels in prostate cancer patients who received treatment for 3 months or longer (Journal of Clinical Oncology 36, no. 15_suppl; NCT03120832).",
            "molecularProfile": {
                "id": 27891,
                "profileName": "ASPH positive"
            },
            "therapy": {
                "id": 5704,
                "therapyName": "PAN-301-1",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11468,
                    "pubMedId": null,
                    "title": "Phase 1 open-label trial to evaluate the safety and immunogenicity of PAN-301-1, a novel nanoparticle therapeutic vaccine, in patients with biochemically relapsed prostate cancer.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e15166"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27891,
            "profileName": "ASPH positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}